Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Single arm, prospective, multi-center, trial designed to enrol approximately 66 patients. All patients will undergo PCI using at least one RISE SC balloon as per routine clinical practice and will be followed until discharge for data collection. Patients will be enrolled in up to 5 investigational sites in Switzerland.
The patients will be followed up until discharge or until 7 days, whichever comes first.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Rise SC | Experimental | All patients will receive the Rise semi-compliant balloon catheter as per treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Balloon dilatation | Device | Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of treated lesions with device success defined as: |
| During the interventional procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with Individual components of device success defined as: |
| During the interventional procedure |
Not provided
Inclusion Criteria:
General Inclusion Criteria
Angiographic Inclusion Criteria All angiographic inclusion criteria are based on visual estimation.
Exclusion Criteria:
General Exclusion Criteria
Angiographic Exclusion Criteria All angiographic exclusion criteria are based on visual estimation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marco Roffi, Dr. | Hôpitaux universitaires de Genève (HUG) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHUV | Lausanne | Canton of Vaud | 1011 | Switzerland | ||
| HVS |
The emphasis in all scientific publications and presentations will be placed on the endpoint at discharge.
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 14, 2023 | |
| Unrelease | Jun 20, 2023 | |
| Release | Jun 26, 2023 | |
| Reset | Feb 15, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 14, 2023 | Jun 20, 2023 | |||
| Jun 26, 2023 |
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Percentage of patients with Procedural success defined as: |
Device success without major adverse cardiovascular events (MACE) which is a composite of all death, myocardial infarction (MI), and clinically indicated target lesion revascularization (CI-TLR) by coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) during the index hospitalization. |
| 1 - 7 Days |
| Percentage of patients with Target Lesion Failure (TLF) | A composite of cardiac death, target vessel myocardial infarction (TV-MI), and CI-TLR by CABG or PCI during the index hospitalization. | 1 - 7 Days |
| Sion |
| Valis |
| 1950 |
| Switzerland |
| HUG | Geneva | 1205 | Switzerland |
| Feb 15, 2024 |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |